Incremental Cost-Effectiveness Ratio and Net Monetary Benefit: Promoting the Application of Value-Based Pricing to Medical Devices—A European Perspective

被引:0
作者
Andrea Messori
Sabrina Trippoli
机构
[1] University of Florence,HTA Unit, ESTAR
[2] Regional Health System,undefined
来源
Therapeutic Innovation & Regulatory Science | 2018年 / 52卷
关键词
cost-effectiveness; medical devices; health economics; incremental cost-effectiveness ratio; net monetary benefit;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:755 / 756
页数:1
相关论文
共 31 条
[1]  
Hwang TJ(2017)Value-based pricing and state reform of prescription drug costs JAMA 318 609-610
[2]  
Kesselheim AS(2014)Sustainable health care systems: the role of therapeutic value and value based pricing Value Health 17 A452-95
[3]  
Sarpatwari A(2013)Value based pricing: Can it work? BMJ 347 f5941-122
[4]  
Hulshof JA(2017)The impact of HTA and procurement practices on the selection and prices of medical devices Soc Sci Med 174 89-30
[5]  
Raftery J(2016)Pharmaceutical regulation in 15 European countries review Health Syst Transit 18 1-2504
[6]  
Callea G(2014)Indication-specific pricing for cancer drugs JAMA 312 1629-453
[7]  
Armeni P(2015)Payer and policy maker steps to support value-based pricing for drugs JAMA 314 2503-768
[8]  
Marsilio M(2017)Incremental cost-effectiveness ratio and net monetary benefit: current use in pharmacoeconomics and future perspectives Eur J Intern Med 43 e36-152
[9]  
Jommi C(2017)Presenting the results of a pharmacoeconomic study: incremental cost-effectiveness ratio vs net monetary benefit Heart 103 1746-378
[10]  
Tarricone R(2016)International Carotid Stenting Study investigators. Cost-utility analysis of stenting versus endarterectomy in the International Carotid Stenting Study Int J Stroke 11 446-undefined